Karan Bhalla, MD
Cardiovascular Disease · Pasadena, TXNPI 1407902794
Payments from drug & device makers
Across 816 payments — averaging $2084.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$966K
- Novartis$397K
- Medtronic$154K
- Amgen$60K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$50K
- AstraZeneca$43K
- plus $33K from 41 others
Across 10 payments — averaging $2740.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vifor (international) Ltd.$27K
What the payments were for
- Consulting fees$18,93148%
- Speaking & faculty fees$1,2503%
- Travel & lodging$3,90510%
- Food & beverage$15,27539%
- Education$2471%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$6,519
- AZUR$675
- Peripheral Orbital Atherectomy System$451
- Coronary Orbital Atherectomy System$451
- COREVALVE EVOLUT R$407
- LUX-DX$357
- EVRSF$327
- ClosureFast$293
- RESONATE$231
- IGT D Peripheral$201
- Hillrom - Carnation Ambulatory Monitor$193
- ATRICLIP LAA EXCLUSION SYSTEM$189
- Farapulse$161
- VIGILANT X4 CRT-D$144
- Perclose ProGlide suture mediated closure system$133
- S-ICD System Magnet$130
- LATITUDE Communicator Power Supply$130
- LATITUDE$123
- Resolute$121
- GENERAL TACHY$119
How this compares
$1,701,324 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 427 | $542,003 |
| XareltoRivaroxaban | 288 | $342,588 |
| EntrestoSacubitril/Valsartan | 251 | $295,561 |
| Repatha SureclickEvolocumab | 25 | $30,333 |
| Repatha SyringeEvolocumab | 24 | $20,266 |
| VascepaIcosapent Ethyl | 19 | $19,763 |
| FarxigaDapagliflozin Propanediol | 23 | $19,565 |
| JardianceEmpagliflozin | 13 | $17,175 |
| Ranolazine ErRanolazine | 105 | $15,160 |
| Metoprolol Succinate | 668 | $9,550 |
| Icosapent Ethyl | 19 | $7,988 |
| Atorvastatin Calcium | 764 | $7,853 |
| ClopidogrelClopidogrel Bisulfate | 562 | $7,567 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 183 | $6,117 |
| Flecainide Acetate | 160 | $5,897 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $380 | $542,003427 claims |
| Johnson & JohnsonXarelto | $589 | $342,588288 claims |
| NovartisEntresto | $396,693 | $295,561251 claims |
| AstraZenecaFarxiga | $42,930 | $19,56523 claims |
| Boehringer IngelheimJardiance | $201 | $17,17513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Pasadena
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
- Fernando BoccalandroOdessa$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.